Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 895929 | ISIN: CH0012142631 | Ticker-Symbol: CLRN
Tradegate
13.02.26 | 13:09
9,120 Euro
-0,33 % -0,030
Branche
Chemie
Aktienmarkt
SMI MID
1-Jahres-Chart
CLARIANT AG Chart 1 Jahr
5-Tage-Chart
CLARIANT AG 5-Tage-Chart
RealtimeGeldBriefZeit
9,1259,17012:07
9,1409,16013.02.
PR Newswire
526 Leser
Artikel bewerten:
(2)

LBB Specialties LLC: LBB Specialties Expands Distribution Partnership with Clariant to Support Puerto Rico's Life Sciences Market

NORWALK, Conn., July 9, 2025 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, is pleased to announce the expansion of its distribution partnership with Clariant, a global leader in the development and manufacturing of specialty chemical solutions. This expansion enhances LBBS's presence in Puerto Rico's robust Life Sciences sector, providing customers with local access to Clariant's pharmaceutical-grade excipients, including the VitiPure product line.

Clariant Logo

Under this expanded agreement, LBB Specialties will now support the Puerto Rico market with Clariant's full excipient portfolio, locally stocked inventory, and dedicated technical and commercial support on the island.

This collaboration strengthens LBBS's ability to deliver high-purity, GMP-compliant excipients tailored for pharmaceutical and biopharmaceutical applications, including products designed for low endotoxin and tight microbial control.

"Puerto Rico continues to be a preferred destination for companies establishing FDA-approved pharmaceutical manufacturing operations," said Seth Burns, Senior Vice President, Life Sciences at LBB Specialties. "By expanding our partnership with Clariant, we're reinforcing our commitment to supporting the region's Life Sciences ecosystem with best-in-class excipients and responsive local service. This expansion builds on our shared vision of advancing formulation innovation while ensuring supply chain reliability and technical excellence."

"This expanded partnership with LBB Specialties represents a strategic advancement in our commitment to strengthening our global footprint," said Vaios Barlas, Head of Health Care at Clariant. "Local availability of our complete excipient portfolio directly addresses the needs of this important market. Clariant values LBBS's established presence and technical capabilities in Puerto Rico, which complement our focus on delivering pharmaceutical-grade ingredients that meet the highest quality and regulatory standards."

For more information about Clariant's excipient solutions in Puerto Rico, please contact LBB Specialties today.

About LBB Specialties
LBB Specialties is a leader in North American specialty chemicals and ingredients distribution. It is a diversified supplier serving end markets including care, food & nutrition, industrial specialties, and life sciences. www.LBBSpecialties.com

About Clariant
Clariant is a focused specialty chemical company led by the overarching purpose of "Greater chemistry - between people and planet." By connecting customer focus, innovation, and people, the company creates solutions to foster sustainability in different industries. On 31 December 2024, Clariant totaled a staff number of 10 465 and recorded sales of CHF 4.152 billion in the fiscal year for its continuing businesses. Since January 2023, the Group conducts its business through the three Business Units Care Chemicals, Catalysts, and Adsorbents & Additives. Clariant is based in Switzerland.

Clariant Health Care is a leading high-quality solution partner for the global pharmaceutical industry, with a strong portfolio of top-performing excipients and active pharmaceutical ingredients (APIs), backed by operational excellence and years of experience in regulatory affairs. https://www.clariant.com/HealthCare

Media Contact:
Ahmed Hanafy
media@lbbspecialties.com

LBB Specialties Logo

Logo - https://mma.prnewswire.com/media/2726987/Clariant_Logo.jpg
Logo - https://mma.prnewswire.com/media/2537440/LBB_Specialties_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/lbb-specialties-expands-distribution-partnership-with-clariant-to-support-puerto-ricos-life-sciences-market-302500574.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.